Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

453 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Validation of MiROvaR, a microRNA-based predictor of early relapse in early stage epithelial ovarian cancer as a new strategy to optimise patients' prognostic assessment.
Ditto A, De Cecco L, Paolini B, Alberti P, Martinelli F, Leone Roberti Maggiore U, Bogani G, Chiodini P, Pignata S, Tomassetti A, Raspagliesi F, Mezzanzanica D, Bagnoli M. Ditto A, et al. Among authors: pignata s. Eur J Cancer. 2022 Jan;161:55-63. doi: 10.1016/j.ejca.2021.11.003. Epub 2021 Dec 15. Eur J Cancer. 2022. PMID: 34922264 Free article.
Activity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6 months: results from the SOCRATES retrospective study.
Pignata S, Ferrandina G, Scarfone G, Scollo P, Odicino F, Cormio G, Katsaros D, Villa A, Mereu L, Ghezzi F, Manzione L, Lauria R, Breda E, Alletti DG, Ballardini M, Lombardi AV, Sorio R, Mangili G, Priolo D, Magni G, Morabito A. Pignata S, et al. BMC Cancer. 2008 Sep 1;8:252. doi: 10.1186/1471-2407-8-252. BMC Cancer. 2008. PMID: 18761742 Free PMC article.
FEZ1/LZTS1 protein expression in ovarian cancer.
Califano D, Pignata S, Pisano C, Greggi S, Laurelli G, Losito NS, Ottaiano A, Gallipoli A, Pasquinelli R, De Simone V, Cirombella R, Fusco A, Chiappetta G. Califano D, et al. Among authors: pignata s. J Cell Physiol. 2010 Feb;222(2):382-6. doi: 10.1002/jcp.21962. J Cell Physiol. 2010. PMID: 19885841
Chemotherapy in epithelial ovarian cancer.
Pignata S, Cannella L, Leopardo D, Pisano C, Bruni GS, Facchini G. Pignata S, et al. Cancer Lett. 2011 Apr 28;303(2):73-83. doi: 10.1016/j.canlet.2011.01.026. Epub 2011 Feb 24. Cancer Lett. 2011. PMID: 21353386 Review.
Efficacy and safety results from OCTAVIA, a single-arm phase II study evaluating front-line bevacizumab, carboplatin and weekly paclitaxel for ovarian cancer.
Gonzalez-Martin A, Gladieff L, Tholander B, Stroyakovsky D, Gore M, Scambia G, Kovalenko N, Oaknin A, Ronco JP, Freudensprung U, Pignata S; OCTAVIA Investigators. Gonzalez-Martin A, et al. Among authors: pignata s. Eur J Cancer. 2013 Dec;49(18):3831-8. doi: 10.1016/j.ejca.2013.08.002. Epub 2013 Sep 2. Eur J Cancer. 2013. PMID: 24007819 Clinical Trial.
Updated results from OCTAVIA (front-line bevacizumab, carboplatin and weekly paclitaxel therapy for ovarian cancer).
Gonzalez-Martin A, Gladieff L, Tholander B, Stroyakovsky D, Gore M, Scambia G, Oaknin A, Sneller V, Freudensprung U, Pignata S; OCTAVIA Investigators. Gonzalez-Martin A, et al. Among authors: pignata s. Eur J Cancer. 2014 Mar;50(4):862-3. doi: 10.1016/j.ejca.2013.12.001. Epub 2014 Jan 10. Eur J Cancer. 2014. PMID: 24418723 No abstract available.
Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial.
Pignata S, Scambia G, Katsaros D, Gallo C, Pujade-Lauraine E, De Placido S, Bologna A, Weber B, Raspagliesi F, Panici PB, Cormio G, Sorio R, Cavazzini MG, Ferrandina G, Breda E, Murgia V, Sacco C, Cinieri S, Salutari V, Ricci C, Pisano C, Greggi S, Lauria R, Lorusso D, Marchetti C, Selvaggi L, Signoriello S, Piccirillo MC, Di Maio M, Perrone F; Multicentre Italian Trials in Ovarian cancer (MITO-7); Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens et du sein (GINECO); Mario Negri Gynecologic Oncology (MaNGO); European Network of Gynaecological Oncological Trial Groups (ENGOT-OV-10); Gynecologic Cancer InterGroup (GCIG) Investigators. Pignata S, et al. Lancet Oncol. 2014 Apr;15(4):396-405. doi: 10.1016/S1470-2045(14)70049-X. Epub 2014 Feb 28. Lancet Oncol. 2014. PMID: 24582486 Clinical Trial.
453 results